Labcorp

Labcorp is a leading global life sciences company that provides comprehensive laboratory services, including diagnostics, drug development, and technology-based solutions. The company operates in two main segments: Diagnostics Laboratories and Biopharma Laboratory Services (comprising Central Laboratories and Early Development Research Laboratories).

Labcorp’s diagnostics Laboratories offer routine and esoteric lab testing services spanning oncology, Alzheimer's, autoimmune diseases, liver diseases, and women's health. The company is expanding its diagnostic capabilities through acquisitions like Invitae assets, and its test menu includes offerings such as pTau217 for Alzheimer's diagnosis, Plasma Detect for colon cancer monitoring.

Further, Labcorp’s Biopharma Laboratory Services provides central lab and early development research support for clinical trials worldwide, its key capabilities including bioavailability, bioequivalence, and pharmacokinetics testing.

In April 2024, Labcorp acquired select assets of Invitae for a sum of USD 239 million.  The acquisition was intended towards leveraging Invitae's assets to scale Labcorp’s specialty testing in areas like oncology and rare diseases. 

Labcorp is operating as a publicly listed company and is traded on the New York Stock Exchange under the ticker symbol LH.

Key customers and partnerships

Labcorp serves a diverse global customer base including pharmaceutical and biotech companies, physicians, hospitals, health systems, consumers, and other laboratories.

The company has entered into several key partnerships and health system agreements, such as with Ascension health system, Baystate Health, Providence and BioReference Health's diagnostic business.

Labcorp also collaborates with various organizations in areas like diversity and inclusion, highlighted in its corporate responsibility initiatives with groups like the Tigerlily Foundation.